News

A new Urban Institute study looks at the availability of antidepressants in marketplace insurance plans.

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis negatively impacts patients.

The Food and Drug Administration last week approved Genvoya, marketed by Gilead Sciences, to treat HIV-1 infection.

CMS recently released 2016 Star Rating data, and the news is not good for many Medicare plans, particularly for standalone Part D prescription drug plans.

Payers are in the strongest-position to activate the transition to value-based management models, but they must improve collaboration with providers.

The risk corridor program was intended to subsidize losses for care for expensive new patients brought in by the ACA, but it's not matching up to reality.

FDA has approved talimogene laherparepvec (Imlygic, Amgen) for the treatment of unresectable melanoma lesions.

An important question is whether improvements in technology can make better control accessible to patients who are not currently good candidates for insulin pumps.

Today’s consumers have high expectations when making a retail purchase. These same demands apply when purchasing health insurance and getting medical care.

Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, will speak about the future of drug development in pulmonary fibrosis during the PFF Summit 2015: From Bench to Bedside conference, November 12-14 in Washington D.C.

A survey of 2,398 physician leaders across the country indicates how physicians are changing their views on value-based care. View the survey findings.

After Valeant and Express Scripts cut ties with mail order specialty pharmacy Philidor Rx Services, the company said it would be closing.

Advancements in IV robotics are mitigating the risks of human error in the compounding process. The misconceptions of IV robotics are many, but there are also many real world examples of how hospitals and health systems are improving processes by implementing technology to support in-house sterile compounding.

Following the ICD-10 transition, real interplay between all stakeholders begins with the patient being the true focus.

While Gilead works on a “cure,” here are four things managed care executives need to know about the current state of HIV treatment

Today’s value-focused economy was a primary discussion point at a recent roundtable of health plan CEOs. The discussion led to five essential attributes that organizations must embrace to thrive.

FDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri Neohaler (glycopyrrolate) – which is one component of Utibron Neohaler -- for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

As healthcare consumerism gains momentum, health plans need to change their offerings to keep up with consumer demands.

While many believe biosimilars have great potential, challenges remain.

These services can detect diseases earlier and prevent them altogether, but rates are lagging behind where they should be.

How advanced use of data and analytics can solve your biggest Star Ratings challenges

New research raises questions on supposed cost savings drive by mail order pharmacies.

Clinically Integrated Networks (CINs) are evolving quickly across the country in response to changing reimbursement trends and the move to value-based payments.

The FDA this week expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma - lowering the risk that melanoma will return following surgery.

A new report looks specifically at spending on healthcare for the privately insured in the U.S in 2014. Here are the findings.

The increasing use of behavioral health medications and polypharmacy in children is concerning, but a new Massachusetts program may help.

During their headline session at the AMCP conference, presenters from Avalere Health shared their predictions for "three futures" in the healthcare market.

The high cost of specialty medications requires an array of management techniques, according to a recent presentation at the Academy of Managed Care Pharmacy Nexus 2015. Read more.